Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an update.
Shanghai Henlius Biotech has received a filing notice from the China Securities Regulatory Commission confirming completion of the regulatory filing for its H share full circulation plan, covering 182,645,856 previously unlisted domestic shares held by certain shareholders. The move paves the way for these domestic shares to be converted into H shares and listed in Hong Kong within 12 months, subject to further procedures required by the Stock Exchange and other regulators, and could enhance liquidity and tradability of the company’s shares, although shareholders and potential investors are cautioned about remaining regulatory steps and related uncertainties.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company listed in Hong Kong that focuses on developing, manufacturing and commercialising biologic drugs, with its capital structure including both domestic shares and H shares traded on the Stock Exchange of Hong Kong, reflecting its orientation toward both mainland Chinese and international investors.
Average Trading Volume: 987,915
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.52B
For an in-depth examination of 2696 stock, go to TipRanks’ Overview page.